Jacobs Levy Equity Management
MTCR

Jacobs Levy Equity Management’s Metacrine, Inc. Common Stock MTCR Stock Holding History

Jacobs Levy Equity Management’s Portfolio MTCR Stock Details MTCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-14,284
Closed -$54K – 1159
2021
Q2 		$54K Sell
14,284
-1,072
-7% -$4.43K ﹤0.01% 1016
2021
Q1 		$95K Buy
+15,356
New +$136K ﹤0.01% 996

Other funds holding MTCR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jacobs Levy Equity Management's MTCR Position: Q3 2021 in Review

Jacobs Levy Equity Management sold out of Metacrine, Inc. Common Stock (MTCR) in Q3 2021, closing a stake of 14,284 shares — an estimated $54K sold.

Jacobs Levy Equity Management first reported a position in MTCR in Q1 2021 and held it in 2 quarters. The position peaked at $95K in Q1 2021. 35 funds tracked by Wall St. Rank hold MTCR as of Q3 2021.

  • Jacobs Levy Equity Management reported no remaining Metacrine, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 14,284 Metacrine, Inc. Common Stock shares in Q3 2021, an estimated $54K.
  • Jacobs Levy Equity Management first reported a position in Metacrine, Inc. Common Stock in Q1 2021 and held it in 2 quarters.
  • Jacobs Levy Equity Management's Metacrine, Inc. Common Stock position peaked at $95K in Q1 2021.
  • 35 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q3 2021.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2021, filed 15 Nov 2021.